L

Louisiana Heart Center | Slidell, LA

Research site

(Unclaimed)

Location

1810 Linberg Drive, Suite 2100, Slidell, Louisiana, United States of America

Site insights

Top conditions

Top treatments

Apixaban

BI 690517

Ranolazine

Iron

Obicetrapib

CK-4021586

Milvexian

Evolocumab

Dapagliflozin

IONIS-AGT-LRx

Parent organization

This site is a part of Louisiana Heart Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 17 total trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

Locations recently updated

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left...

Enrolling

Heart Failure

Drug: empagliflozin

Drug: placebo

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

Enrolling

Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

Drug: Placebo to match CK-4021586

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardi...

Enrolling

Cardiovascular Disease

Drug: Olpasiran

Drug: Placebo